Search by alphabetical order

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Back

Simone Chevalier, PhD

Research Institute of the McGill University Health Centre

Regular Member
Endocrinology, Diabetes, Nutrition and Kidney Diseases


McGill University Health Centre (MUHC)

Medical Scientist


McGill University

Departement of Surgery, Departement of Medicine, Departement of Oncology


Research Interest


My research focuses on prostatic diseases, benign prostatic hyperplasia (BPH) and prostate cancers (PCa) that spontaneously arise in men 50 years or older. Our mechanistic studies involve the use of diverse in vitro and in vivo approaches to characterise key molecules of signaling pathways mediated by androgens and growth-promoting factors in heterogeneous cell populations of the human and dog prostate cells, tumours and metastases. We also focus on circulatory molecules as potential biomarkers of PCa witnessing tumor cells as they evolve with progression. To translate our findings to patients, we implemented a PCa biobank and adopted a large animal (canine) model of PCa.

Research Foci


  • androgen dependency, sensitivity and independency of prostate cells
  • involvement of prostate stem cells in prostatic diseases
  • implication of the tyrosine kinases Fer and Fak and their substrates and partners in prostate cancer progression
  • signaling in response to androgens, cytokines, growth factors and neuro-products
  • prostate cancer biomarkers in blood, urine and tissues

Keywords


Prostate, prostate cancer, signaling, tyrosine kinases, biomarkers, STAT3, androgen receptor, stem cells, neuroendocrine cells, androgen independence

Selected Publications


Click on Pubmed to see my current publications list

  • Rocha J, Zouanat F, Zoubeidi A, Hamel L, Benidir T, Scarlata E. Brimo F, Aprikian A, Chevalier S. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Mol. Cell. Mol Cell Endocrinol. 2013 Jul 30; 381(1-2):140-149.

  • Chevalier S, Cury F, Scarlata E, El-Zayat E, Hamel L, Rocha J, Zouanat F, Moussa S, Scherz A, Elhilali M, Anidjar M. Endoscopic vascular targeted photodynamic therapy with the photosensitizer TOOKADSoluable WST11 for benign prostatic hyperplasia in the pre-clinical dog model. J Urol. 2013 May 13. PMID: 23680311

  • Anidjar A, Scarlata E., Cury FL, Rocha J., Hamel L., Luz M., Chevalier S. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. The Prostate. 72 (7): 752–761, 2012; 2011 Aug 31: 10.1002/pros.21479.

  • Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell Tissue Bank. 2012 Dec;13(4):631-8. doi: 10.1007/s10561-011-9284-y. Epub 2011 Dec 2

  • Zoubeidi A., Cury-Rocha J., Zouanat F., Hamel L., Scarlata E., Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate the signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res; 7, 142-155, 2009.